Chordia Therapeutics (TSE:190A) Total Assets: 円2,512.26 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Total Assets?

Chordia Therapeutics TSE:190A -2.53% 11 Total Assets is 円2,512.26 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Chordia Therapeutics's Total Assets for the quarter that ended in Feb. 2026 was 円2,512.26 Mil.

During the past 12 months, Chordia Therapeutics's average Total Assets Growth Rate was -56.30% per year. During the past 3 years, the average Total Assets Growth Rate was -18.40% per year.

During the past 5 years, Chordia Therapeutics's highest 3-Year average Total Assets Growth Rate was 3.50%. The lowest was -18.40%. And the median was -7.45%.

Total Assets is connected with ROA %. Chordia Therapeutics's annualized ROA % for the quarter that ended in Feb. 2026 was -48.81%. Total Assets is also linked to Revenue through Asset Turnover. Chordia Therapeutics's Asset Turnover for the quarter that ended in Feb. 2026 was 0.00.

Chordia Therapeutics  (TSE:190A) Total Assets Explanation

Total Assets is connected with ROA %.

Chordia Therapeutics's annualized ROA % for the quarter that ended in Feb. 2026 is

ROA %=Net Income (Q: Feb. 2026 )/( (Total Assets (Q: Aug. 2025 )+Total Assets (Q: Feb. 2026 ))/ count )
=-1267.406/( (2681.349+2512.264)/ 2 )
=-1267.406/2596.8065
=-48.81 %

Note: The Net Income data used here is two times the semi-annual (Feb. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Chordia Therapeutics's Asset Turnover for the quarter that ended in Feb. 2026 is

Asset Turnover
=Revenue (Q: Feb. 2026 )/( (Total Assets (Q: Aug. 2025 )+Total Assets (Q: Feb. 2026 ))/ count )
=0/( (2681.349+2512.264)/ 2 )
=0/2596.8065
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Chordia Therapeutics Total Assets Related Terms

Chordia Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Total Assets Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Total Assets
2,271.38 4,498.95 4,909.12 4,632.37 2,681.35

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Total Assets Get a 7-Day Free Trial 0.00 4,632.37 3,451.52 2,681.35 2,512.26
TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Chordia Therapeutics's Total Assets for the fiscal year that ended in Aug. 2025 is calculated as

Total Assets=Total Equity (A: Aug. 2025 )+Total Liabilities (A: Aug. 2025 )
=2437.01+244.339
=2,681.35

Chordia Therapeutics's Total Assets for the quarter that ended in Feb. 2026 is calculated as

Total Assets=Total Equity (Q: Feb. 2026 )+Total Liabilities (Q: Feb. 2026 )
=2315.024+197.24
=2,512.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of 円2,512.26 Mil mean?
Chordia Therapeutics (TSE:190A) has a Total Assets of 円2,512.26 Mil as of Feb. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' Total Assets too high?
Chordia Therapeutics' current Total Assets is 円2,512.26 Mil. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Total Assets compare to VRTX and REGN?
Chordia Therapeutics' Total Assets of 円2,512.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Total Assets is 円2,512.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Total Assets of 円2,512.26 Mil. The current Total Assets is 円2,512.26 Mil. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Total Assets is 円2,512.26 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price